A targeted cancer drug has been approved for use on the NHS in Scotland for patients with advanced, newly diagnosed ovarian cancer that’s responded to chemotherapy. Olaparib (Lynparza) tablets will be used to help prolong the effects of initial treatment, as a so-called…
The National Institute for Health and Care Excellence (NICE) has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England. Trial results have shown that olaparib, which stops cancer cells repairing damage to their DNA, can…
A blood test can help identify rare mutations in advanced breast cancer, which may enable patients to access effective treatments more quickly in the future, Cancer Research UK scientists have found. As part of the plasmaMATCH clinical trial, funded by Stand Up To Cancer, a joint…
2019 was a year jam packed with  brilliant progress and  new  challenges for cancer research. Here are some of the top stories of the year: Re-writing the breast cancer rulebook, A cancer breath test enters trials, three new teams take on some of the biggest challenges in cancer research, tracking cancer evolution with…
Cancer Research UK and Vaccitech Oncology Limited (VOLT), announced Wednesday that a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer. The vaccine treatment developed by VOLT, a strategic collaboration between Vaccitech Ltd and the Ludwig Institute for Cancer Research, is…
New headlines on cancer research:
-A prostate cancer MRI trial is in progress
-Treatment that delivers drugs straight to tumor given for the first time
-WHO approves cheap copy of common breast cancer drug
-Facebook bans ads promoting fake cancer "cures"
-Post-menopausal women who are overweight…
The US Chinese Anti-Cancer Association and the Asian Fund for Cancer Research jointly awarded five outstanding Chinese cancer researchers in the early stages of their careers with the 2019 USCACA-AFCR Young Investigator Award (also known as the USCACA-AFCR Scholar Award of Clinical,…
The 2019 Give to Cure Cancer Year-End Appeal is now underway. It’s your chance to make this year’s campaign the most successful ever.
This past year, we continued to fund several promising cancer research programs. With support from loyal donors like you, excellent…
Specialists warn that single number average survival estimates for advanced stage breast cancer are unhelpful and usually inaccurate. Instead, they advise doctors to provide several case-specific survival estimates to help people plan with realism and hope. Breast cancer is the form of cancer that affects women…
The U.S. Food and Drug Administration recently approved a treatment that combines an immunotherapy drug and chemotherapy for triple negative breast cancer, but not all cases of this aggressive form of breast cancer responded in clinical studies. UNC Lineberger researchers discovered biological…
